Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study (Q35582894)
Jump to navigation
Jump to search
scientific article published on June 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study |
scientific article published on June 2015 |
Statements
1 reference
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study (English)
1 reference
Annamaria Colao
1 reference
Laura De Marinis
1 reference
Michael Sheppard
1 reference
Marcello D Bronstein
1 reference
Pamela Freda
1 reference
Omar Serri
1 reference
Luciana Naves
1 reference
Liudmila Rozhinskaya
1 reference
Karina Hermosillo Reséndiz
1 reference
Matthieu Ruffin
1 reference
YinMiao Chen
1 reference
8 August 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference